Press Releases & News

SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced that the CEO of Calidi Biotherapeutics, Allan Camaisa, received the Pillars of Hope Award by the Mitchell Thorp Foundation.…

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George Ng, Partner of PENG Life Science Ventures. His extensive background includes co-founding and leading the efforts of…

SAN DIEGO, CA / ACCESSWIRE / September 18, 2019 / Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced that they were named one of the "50 Most Trustworthy Companies of the Year" for 2019 by The Silicon Review magazine.…

SAN DIEGO, CA / ACCESSWIRE / August 29, 2019 / Calidi Biotherapeutics Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer announced today, the completion of the adipose tissue collection from healthy donors necessary for isolation of adipose-derived mesenchymal stem cells (AD-MSC) -…

Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of a distinguished innovator in the field of cancer diagnosis and treatment, Ewa Carrier, MD, to their medical and scientific advisory board. Dr. Carrier has…

SAN DIEGO, CA / ACCESSWIRE / July 10, 2019 / Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of stem cell-based delivery of oncolytic virus-based immunotherapies for cancer, today announced an exclusive veterinary worldwide license for the development and commercialization of its lead…

SAN DIEGO (PRWEB) JUNE 03, 2019 - Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of Dr. Dmitriy Zamarin, MD, Ph.D., to their scientific advisory board. Dr. Zamarin is an accomplished medical oncologist who…

SAN DIEGO, May 30, 2019 /PRNewswire/ -- Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive: Dr. Ashok Srivastava, MD, Ph.D., MBA, to their scientific advisory board. Dr. Srivastava's notable achievements include contributions to…

SAN DIEGO, May 28, 2019 /PRNewswire/ -- Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced their ongoing scientific collaboration with David F. Stroncek, M.D., Chief, Cell Therapy Section at the Department of Transfusion Medicine, National Institutes of Health (NIH)…

SAN DIEGO (PRWEB) APRIL 15, 2019 Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that Allan Camaisa, Calidi Biotherapeutics CEO, and San Diego based serial entrepreneur, was interviewed by San Diego’s local news station KUSI.…